// App-Quantinova.ai

9077 : A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Researchers

Presenter

  • Fabrice Barlesi

Principal Investigators

  • Judith Raimbourg

  • Pascal Do

  • Patrick Dumont

  • Jacques Cadranel

  • Didier Debieuvre

  • Werner Hilgers

  • Pierre Jean Souquet

  • Olivier Molinier

  • Elisabeth A. Quoix

  • Alexandra Langlais

  • Marie Paule Lebitasy

  • Franck Morin

  • Gerard Zalcman

  • Jaafar Bennouna

Medical Centers

  • Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • Centre Francois Baclesse, Caen, France

  • Centre Hospitalier De Chauny - Service de Pneumologie, Chauny, France

  • Hopital Tenon, AP-HP and Faculte de Medecine Pierre et Marie Curie, Universite Paris VI, Paris, France

  • Emile Muller Hospital, Mulhouse, France

  • Institut Sainte Catherine, Avignon, France

  • Hopital Lyon Sud, Pierre-Benite, France

  • Le Mans Regional Hospital, Le Mans, France

  • University Hospital of Strasbourg, Strasbourg, France

  • IFCT, Paris, France

  • Intergroupe Francophone de Cancerologie Thoracique, Paris, France

  • CHU Caen, Caen, France

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT01705184

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved